Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.

Bryan LiThomas YauRoland LeungGerry KwokJosephine TsangPolly CheungT T WongDacita SuenAva KwongJoanne Wing Yan Chiu

Published in: Advances in therapy (2021)

Six cycles of TEC with prophylactic G-CSF is an effective and tolerable neoadjuvant regime for HER2-negative breast cancers. Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
locally advanced
rectal cancer
peritoneal dialysis
prognostic factors
lymph node
patient reported outcomes